Primary prevention with vaginal chlorhexidine before 16 weeks reduces the incidence of preterm birth: results of the Preterm Labor Prevention Using Vaginal Antiseptics study.
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Alamo, Blanca Novillo-Del
Grupos
Abstract
BACKGROUND: Preterm labor is one of the leading causes of perinatal death and is currently considered a syndrome with many causes. One of the most important causes of preterm birth is ascending infection from bacterial vaginosis. Chlorhexidine has proven to be effective against bacterial vaginosis and against bacterial biofilms without affecting gestation. OBJECTIVE: We aimed to evaluate the effectiveness of a universal primary prevention strategy for preterm birth using intravaginal chlorhexidine applied before 16 weeks (Preterm Labor Prevention Using Vaginal Antiseptics study). STUDY DESIGN: We performed a prospective observational study with 2 cohorts of pregnant women that were assigned either to prevention of preterm birth by means of intravaginal chlorhexidine (Cum Laude Chlorhexidine, chlorhexidine digluconate 0.2%) before 16 weeks (n=413), or to no treatment following the usual hospital protocol (n=704). Primary outcomes were the incidence of spontaneous preterm birth before 34 and 37 weeks; the incidence of preterm birth before 34 and 37 weeks, including inductions for premature rupture of membranes; and the incidence of preterm birth before 34 and 37 weeks, including any indication for termination of pregnancy. Both cohorts were compared using Mann-Whitney and Fisher tests. Finally, a multivariable analysis, including the odds ratio was performed, adjusting for clinical parameters, to evaluate the importance of the different determinants in the prediction of preterm birth. RESULTS: In pregnancies treated with chlorhexidine, the incidences of spontaneous preterm birth; preterm birth, including induction for premature rupture of membranas; and preterm birth, including any indication for termination of pregnancy were at 34 and 37 weeks: 0% and 0%, 0.24% and 1.69, and 2.90% and 3.15%, respectively; whereas in nontreated pregnancies, these incidences were 9% and 11%, 12% and 23%, and 35% and 43%, respectively. According to the multivariable analysis, the incidence of preterm birth among women treated with chlorhexidine before 16 weeks was halved (Odds ratio, 0.52; P<.05). CONCLUSION: Universal treatment with vaginal chlorhexidine before 16 weeks reduces the incidence of preterm birth, especially before 34 weeks.
© 2023 The Authors.
Datos de la publicación
- ISSN/ISSNe:
- 2666-5778, 2666-5778
- Tipo:
- Article
- Páginas:
- 100277-100277
Ajog Global Reports
Documentos
- No hay documentos
Filiaciones
Filiaciones no disponibles
Keywords
- bacterial vaginosis; chlorhexidine; labor onset; premature rupture of membranas; preterm birth; primary prevention; vaginal dysbiosis
Proyectos asociados
UTILIDAD DEL TRATAMIENTO TOCOLITICO DE MANTENIMIENTO EN EL MANEJO DE LA AMENAZA DE PARTO PREMATURO (APP)
Investigador Principal: MÁXIMO VENTO TORRES
EC11-246 . 2012
RED DE SALUD MATERNO INFANTIL Y DEL DESARROLLO
Investigador Principal: MÁXIMO VENTO TORRES
RD12/0026/0012 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2013
PAPEL DEL FACTOR DE CRECIMIENTO PLACENTARIO EN EL MANEJO DE LA PREECLAMPSIA NO SEVERA: ESTUDIO ALEATORIZADO
Investigador Principal: ALFREDO JOSÉ PERALES MARÍN
PI15/01935 . INSTITUTO DE SALUD CARLOS III . 2016
Iplacenta. innovation in pacenta modelling for maternal and fetal health.
Investigador Principal: JOSÉ MORALES ROSELLÓ
765274 . COMISION EUROPEA . 2018
ENSAYO MULTICÉNTRICO, ABIERTO, ALEATORIZADO, DE DOSIS ÚNICA, CONTROLADO, DE XOMA 213 ADMINISTRADO POR VÍA INTRAVENOSA A MUJERES DESPUÉS DEL PARTO PARA LA SUPRESIÓN DE LA LACTANCIA.
Investigador Principal: ALFREDO JOSÉ PERALES MARÍN
X213220
ENSAYO EN FASE III, ALEATORIZADO, DOBLE CIEGO O CON ENMASCARAMIENTO PARA EL OBSERVADOR, CONTROLADO CON PLACEBO, PARA EVALUAR LA EFICACIA Y SEGURIDAD DE UNA VACUNA DE SUBUNIDAD F PREFUSIÓN CONTRA EL VIRUS RESPIRATORIO SINCITIAL (VRS) EN LACTANTES NACIDOS D E MUJERES VACUNADAS DURANTE EL EMBARAZO
Investigador Principal: EMILIO MONTEAGUDO MONTESINOS
C3671008 . 2020
ESTUDIO FASE 2/3 CONTROLADO CON PLACEBO, ALEATORIZADO, CEGADO PARA EL OBSERVADOR, PARA EVALUAR LA SEGURIDAD, LA TOLERABILIDAD Y LA INMUNOGENICIDAD DE UNA VACUNA CANDIDATA DE ARN (BNT162B2) DEL SARS-COV-2, CONTRA COVID-19 EN MUJERES EMBARAZADAS SANAS DE 18 AÑOS DE EDAD Y MAYORES.
Investigador Principal: VICENTE JOSE DIAGO ALMELA
C4591015 . 2021
EVALUACIÓN DE LA EFICACIA DEL USO DE CLORHEXIDINA DURANTE EL PRIMER TRIMESTRE COMO REGULADOR DE LA MICROBIOTA VAGINAL EN LA REDUCCIÓN DE PARTO PREMATURO.
Investigador Principal: JOSÉ MORALES ROSELLÓ
PLUVA . 2021
Comparison of maternal-fetal outcomes among unvaccinated and vaccinated pregnant women with Covid-19.
Investigador Principal: ALICIA MARTÍNEZ VAREA
CoVaGest . 2022
Elaboración de un algoritmo de predicción de parto tras inducción basado en criterios clínicos, epidemiológicos y ecográficos.
Investigador Principal: JOSÉ MORALES ROSELLÓ
Prepain . 2023
Spanish Analysis of PostPartum Haemorrhage Incidence and Real Evidence - Organon” (SAPPHIRE-O).
Investigador Principal: VICENTE JOSE DIAGO ALMELA
SAPPHIRE-O . 2023
Cita
Morales J,Loscalzo G,Martinez A,Alamo BN,Nieto M. Primary prevention with vaginal chlorhexidine before 16 weeks reduces the incidence of preterm birth: results of the Preterm Labor Prevention Using Vaginal Antiseptics study. AJOG Glob Rep. 2023. 3. (4):p. 100277-100277.